Education
About Us
Working with TipRanks
Follow Us
Baxter International (BAX)
NYSE:BAX
BAX Stock Chart & Stats
$18.26
$0.05(0.17%)
At close: 4:00 PM EST
$18.26
$0.05(0.17%)
Day’s Range― - ―
52-Week Range$17.40 - $37.74
Previous CloseN/A
Volume899.70K
Average Volume (3M)9.00M
Market Cap
$9.34B
Enterprise Value$19.66B
Total Cash (Recent Filing)$1.73B
Total Debt (Recent Filing)$9.71B
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Feb 12, 2026EPS Estimate
0.54Last Dividend Ex-Date
Nov 28, 2025Dividend Yield2.85%
Share Statistics
EPS (TTM)0.69
Shares Outstanding514,055,800
10 Day Avg. Volume6,715,531
30 Day Avg. Volume9,000,971
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.14
Price to Sales (P/S)1.40
P/FCF Ratio26.60
Enterprise Value/Market Cap2.11
Enterprise Value/Revenue1.78
Enterprise Value/Gross Profit5.04
Enterprise Value/Ebitda19.15
Forecast
1Y Price Target
$23.22Price Target Upside27.16% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceDespite challenges, adjusted EPS of $0.69 surpassed the consensus estimate of $0.60, aided by a lower-than-expected tax rate.
Leadership StrategyCEO Andrew Hider introduced a near-term action plan focusing on business stabilization, balance sheet enhancement, and operational efficiency improvement.
Turnaround InitiativesTurnaround initiatives, including the dividend cut, offer the opportunity for Baxter to enhance fundamentals over time.
Bears Say
Future OutlookThe 2026 outlook moves meaningfully lower, demonstrating anticipation of BAX facing continued headwinds.
Growth GuidanceThe company reduced its full-year operational sales guidance to 1-2% from previous estimates of 3-4% and also lowered its EPS guidance.
Sales PerformanceBaxter International's Q3 revenue of $2.82 billion fell short of the $2.88 billion consensus, indicating challenges in achieving expected growth.
Baxter International News
BAX FAQ
What was Baxter International’s price range in the past 12 months?
Baxter International lowest stock price was $17.40 and its highest was $37.74 in the past 12 months.
What is Baxter International’s market cap?
Baxter International’s market cap is $9.34B.
When is Baxter International’s upcoming earnings report date?
Baxter International’s upcoming earnings report date is Feb 12, 2026 which is in 62 days.
How were Baxter International’s earnings last quarter?
Baxter International released its earnings results on Oct 30, 2025. The company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.598 by $0.092.
Is Baxter International overvalued?
According to Wall Street analysts Baxter International’s price is currently Undervalued.
Does Baxter International pay dividends?
Baxter International pays a Quarterly dividend of $0.01 which represents an annual dividend yield of 2.85%. See more information on Baxter International dividends here
What is Baxter International’s EPS estimate?
Baxter International’s EPS estimate is 0.54.
How many shares outstanding does Baxter International have?
Baxter International has 514,055,800 shares outstanding.
What happened to Baxter International’s price movement after its last earnings report?
Baxter International reported an EPS of $0.69 in its last earnings report, beating expectations of $0.598. Following the earnings report the stock price went down -14.547%.
Which hedge fund is a major shareholder of Baxter International?
Currently, no hedge funds are holding shares in BAX
Baxter International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$23.22 (27.16% Upside)
$23.22 (27.16% Upside)
Blogger Sentiment
Bearish
BAX Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 29.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 19.6%
Last 30 Days ▲ 19.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.86%
12-Months-Change
Fundamentals
Return on Equity
-4.70%
Trailing 12-Months
Asset Growth
-21.03%
Trailing 12-Months
Company Description
Baxter International
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
BAX Company Deck
BAX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Baxter International's earnings call highlighted revenue growth in key segments, particularly in Advanced Surgery and Healthcare Systems & Technologies. However, significant challenges exist, notably with the Infusion Therapies and Pharmaceuticals segments, as well as the decision to reduce the dividend for deleveraging purposes. The company's focus on stabilizing business operations, improving the balance sheet, and driving continuous improvement reflects a proactive approach to addressing these challenges.View all BAX earnings summariesBAX Net sales Breakdown
48.96% Medical Products and Therapies
27.75% Healthcare Systems and Technologies
22.67% Pharmaceuticals
0.63% Other
BAX Stock 12 Month Forecast
Average Price Target
$23.22
▲(27.16% Upside)
Technical Analysis
Ownership Overview
0.46% Insiders
33.79% Mutual Funds
32.85% Other Institutional Investors
7.18% Public Companies and
Individual Investors